Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease
Zhou Z, Price CC. Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease. Expert Opinion On Investigational Drugs 2020, 29: 1407-1412. PMID: 33094669, DOI: 10.1080/13543784.2020.1840549.BooksConceptsCytokine release syndromeIL-6 inhibitorsRelease syndromeSafety profileInterleukin-6Mild safety profileRandomized clinical trialsTreatment of patientsAvailable clinical dataCOVID-19COVID-19 diseaseCOVID-19 managementNovel coronavirus pneumoniaHyperinflammatory stateClinical outcomesHealthcare burdenClinical trialsClinical dataObservational studyImmune responseLong-term effectsClinical reportsLiterature searchCoronavirus pneumoniaTocilizumab